Germline ATM Variants Impact Development of CLL
Inherited germline variation can predispose individuals to cancer and affect the biology of the...
Read More
Hematology/Oncology
Electroacupuncture Cuts Risk for Prolonged Postoperative Ileus
FRIDAY, Nov. 4, 2022 (HealthDay News) — Electroacupuncture (EA) is effective in promoting...
Read More
Impaired Chromatin Remodeling: GS plus Nivolumab in ABTC
Researchers’ prior research indicated that the combination of modified gemcitabine and S-1...
Read More
Frailty-Related Fracture Risk Higher for Seniors With Cancer History
THURSDAY, Nov. 3, 2022 (HealthDay News) — Older adults with a history of cancer have an...
Read More
Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced NSCLC
In the CHOICE-01 research, toripalimab and chemotherapy were used as the first-line therapy for...
Read More
Progression and Survival of Monoclonal B-cell lymphocytosis (MBL)
A typical hematological premalignant disease that is understudied in screening cohorts is...
Read More
Loss of Sphingosine Kinase 2 Promotes the HSCs Expansion
During myelosuppressive injury or age, hematopoietic stem cells (HSCs) have diminished abilities...
Read More
Prognostic Impact of NPM1 & FLT3 Mutations in AML Patients
The oral azacitidine (Oral-AZA) was tested in patients with acute myeloid leukemia (AML) in the...
Read More
Surveillance Feasible for Women Deferring Prophylactic Salpingo-Oophorectomy
WEDNESDAY, Nov. 2, 2022 (HealthDay News) — For women deferring risk-reducing bilateral...
Read More
Older Adults With Poor-Prognosis Cancers Commonly Have Preexisting Conditions
WEDNESDAY, Nov. 2, 2022 (HealthDay News) — Preexisting conditions that affect physical...
Read More
Nivolumab & Gemcitabine in Recurrent or Metastatic NPC Patients
In this trial, the effectiveness and safety of nivolumab with gemcitabine were assessed for...
Read More
ARX788, Anti-HER2 ADC, for HER2-Positive MBC Treatment
ARX788 is a novel antibody-drug conjugate (ADC) that combines an anti-HER2 mAb with a potent...
Read More
Omission of Upfront CSI in Low-Risk WNT-Pathway Medulloblastoma
There are 4 molecular subgroups of medulloblastoma: wingless (WNT), sonic hedgehog (SHH), group 3,...
Read More
A Study of TB-403 in Relapsed Medulloblastoma, Neuroblastoma, Ewing Sarcoma, And Alveolar Rhabdomyosarcoma
Placental growth factor (PlGF) and its receptor neuropilin 1 are increased in malignant embryonal...
Read More
Interval & Resistance Training Benefit Patients With CLL
For patients with CLL, clinically significant improvements linked with a 12-week HIIT+RT exercise...
Read More
Differentiated Thyroid Cancer: Cabozantinib Approval Summary
On September 17, 2021, the FDA approved cabozantinib (Cabometyx; Exelixis, Inc.) for the treatment...
Read More
Radioiodine Incorporation into RR-TC with MAPK Inhibition (ERRITI)
In radioiodine-resistant, resectable thyroid cancer, inhibition of mitogen-activated protein...
Read More
Leukemia Relapse Associated with TIGIT- and CD161-expressing CD4 T Cells
The best course of treatment for certain patients with acute myeloid leukemia (AML) is allogeneic...
Read More
In Hematopoietic Stem Cells, Physioxia Induces Tet2 Downregulation
When exposed to ambient air as compared to physioxia, hematopoietic stem cells (HSCs) exhibit...
Read More
1999 to 2018 Saw Increase in Barriers to Timely Medical Care
FRIDAY, Oct. 28, 2022 (HealthDay News) — From 1999 to 2018, barriers to timely medical care...
Read More